10 results on '"Gervasi, E."'
Search Results
2. Additional file 2 of Taxonomic reclassification of Kaposi Sarcoma identifies disease entities with distinct immunopathogenesis
- Author
-
Openshaw, M. R., Gervasi, E., Fulgenzi, C. A. M., Pinato, D. J., Dalla Pria, A., and Bower, M.
- Abstract
Additional file 2. On median overall survival.
- Published
- 2023
- Full Text
- View/download PDF
3. Additional file 3 of Taxonomic reclassification of Kaposi Sarcoma identifies disease entities with distinct immunopathogenesis
- Author
-
Openshaw, M. R., Gervasi, E., Fulgenzi, C. A. M., Pinato, D. J., Dalla Pria, A., and Bower, M.
- Abstract
Additional file 3. Clinicopathological features and virological parameters of patients with Classical versus Endemic KS.
- Published
- 2023
- Full Text
- View/download PDF
4. Association of Arthroscopically-Assisted Latissimus Dorsi Tendon Transfer with Implantation of a Subacromial Balloon Spacer for Patients with Irreparable Posterosuperior Rotator Cuff Tears
- Author
-
Gervasi E., Vigni G. E., Vezeridis P. S., Tomasi A., Sabbioni G., Fazzari F., Camarda Lawrence, Gervasi E., Vigni G.E., Vezeridis P.S., Tomasi A., Sabbioni G., Fazzari F., and Camarda Lawrence
- Subjects
latissimus dorsi ,tendon transfer ,Shoulder ,subacromial spacer ,Settore MED/33 - Malattie Apparato Locomotore ,Orthopedics and Sports Medicine ,rotator cuff ,arthroscopy - Abstract
Purpose. Massive irreparable posterosuperior rotator cuff tears in an active population, resulting in a pseudo-paralytic shoulder, pose a challenge for the orthopaedic surgeon. In an effort to avoid or delay arthroplasty surgery, other surgical strategies such as arthroscopically-assisted latissimus dorsi transfer (aLDT) or the implantation of a subacromial spacer (SAS) can be considered. The aim of the present study is to associate, for the first time, these two surgical procedures in order to demonstrate the surgical feasibility and the effectiveness of their synergistic biomechanical effect. Methods. The study group consisted of patients who underwent aLDT for a massive irreparable posterosuperior rotator cuff tear with or without SAS placement. The study population consisted of 17 patients. Patients were assessed with the following outcomes scores: Constant and Murley Score (CMS), Disability of Arm, Shoulder and Hand (DASH), Oxford Shoulder Score (OSS), and Subjective Shoulder Value (SSV). Follow-up after surgery (T0) took place at the following time points: 40 days (T1), 3 months (T2), 9 months (T3), and 12 months (T4). Statistical analysis was performed by descriptive statistics, nonparametric ANOVA test, and a multivariate linear regression model. The effect of subscapularis repair on clinical outcomes was also examined with subgroup analysis. Results. In the entire population, the mean change in scores between T0 and T4 was: +30.5 for CMS,-35.14 for DASH, +18.06 for OSS, +40.47 for SSV. A statistically significant increase in all scores for both aLDT alone and aLDT with concomitant SAS was detected starting as early as T2. The subscapularis repair group had the following results as compared with the subscapularis intact group: CMS-9.5580 (p = 0.0164), OSS-5.6873 (p = 0.0378), and DASH +21.0424 (p = 0.0097). Conclusions. This study demonstrates, for the first time, the feasibility and efficacy of the arthroscopically-assisted latissimus dorsi transfer alone and with concomitant implantation of a subacromial spacer. Both surgeries demonstrate clinical efficacy as early as three months after surgery, with significant and progressive clinical improvements through 12 months postoperatively. © 2022, EDRA S.p.A. All rights reserved.
- Published
- 2022
5. The Italian Consensus Conference on FAI Syndrome in Athletes (Cotignola Agreement)
- Author
-
Zini, R., Panasci, M., Santori, N., Potestio, D., Di Pietto, F., Milano, G., Gervasi, E., Falez, F., Castelli, C., Aprato, A., Auci, A., Baffoni, L., Benelli, P., Bianchi, L., Bigoni, M., Bisciotti, A., Bona, S., Carraro, A., Carulli, C., Cassaghi, G., Catani, F., Cerulli, S., Conati, M., Corsini, A., Costantini, A., Dallari, D., Dall'Oca, C., Della Rocca, F., De Nardo, P., Di Benedetto, P., Di Muzio, F., Fabris, T., Fiorentino, G., Fioruzzi, A., Foglia, A., Fogli, M., Fontana, A., Gallo, E., Via, A. G., Giammattei, C., Giuliani, P., Grano, G., Guglielmi, A., Longo, G. U., Mazzoni, G., Moretti, B., Moretti, L., Munegato, D., Nanni, G., Occhialini, M., Papalia, R., Parra, M. F., Ruiz, M. T. P., Pierannunzii, L., Pirani, P., Ponzetto, G., Randelli, F., Sabetta, E., Serafini, S., Stagni, C., Tombari, E., Trento, F. M., Volpi, P., and Bisciotti, G. N.
- Subjects
return to play ,Pincer-FAI ,surgical treatment ,Cam-FAI ,rehabilitation ,Orthopedics and Sports Medicine - Published
- 2023
6. Propensity Score and Desirability of Outcome Ranking Analysis of Ertapenem for Treatment of Nonsevere Bacteremic Urinary Tract Infections Due to Extended-Spectrum-Beta-Lactamase-Producing Enterobacterales in Kidney Transplant Recipients
- Author
-
Gutierrez-Gutierrez, B., Perez-Nadales, E., Perez-Galera, S., Fernandez-Ruiz, M., Carratala, J., Oriol, I., Cordero, E., Lepe, J. A., Tan, B. H., Corbella, L., Paul, M., Natera, A. M., David, M. D., Montejo, M., Iyer, R. N., Pierrotti, L. C., Merino, E., Steinke, S. M., Rana, M. M., Munoz, P., Mularoni, A., van Delden, C., Grossi, P. A., Seminari, E. M., Gunseren, F., Lease, E. D., Roilides, E., Fortun, J., Arslan, H., Coussement, J., Tufan, Z. K., Pilmis, B., Rizzi, M., Loeches, B., Eriksson, B. M., Abdala, E., Soldani, F., Lowman, W., Clemente, W. T., Bodro, M., Farinas, M. C., Kazak, E., Martinez-Martinez, L., Aguado, J. M., Torre-Cisneros, J., Pascual, A., Rodriguez-Bano, J., Sabe, N., Camoez, M., Martin-Gandul, C., Bernal, G., Kee, T. Y. S., Lopez-Medrano, F., Juan, R. S., Koppel, F., Bar-Sinai, N., Caston, J. J., Cano, A., Gracia-Ahufinger, I., Rodriguez, R., Lopez-Soria, L., Azurmendi, M., Pinheiro, M., Freire, M., Banks, I., Lopes, F., David-Neto, E., Balibrea, N., Franco, A., Avery, R., Ostrander, D., Minero, M. V., Carrillo, C. S., Rodriguez-Ferrero, M. L., Monaco, F., Campanella, M., Mueller, N. J., Manuel, O., Khanna, N., Rovelli, C., Balsamo, M. L., Colombo, A., Leoni, C., Pyrpasopoulou, A., Mouloudi, E., Iosifidis, E., Martin-Davila, P., Gioia, F., Escudero, R., Demirkaya, M. H., Dewispelaere, L., Kalem, A. K., Hasanoglu, I., Guner, R., Lortholary, O., Scemla, A., Calvi, E. G., Gervasi, E., Binda, F., Oliva, M. L., Dimopoulos, N., Magalhaes, M. R., Song, A. T. W., D'Albuquerque, L. A. C., Chiesi, S., Salerno, N. D., Mourao, P. H. O., Moreno, A., Linares, L., Almela, M., Rico, C. G., Rodrigo, E., Martinez, M. F., Falcone, M., Tumbarello, M., Strabelli, T. M. V., Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades (España), Red Española de Investigación en Patología Infecciosa, European Commission, Sociedad Andaluza de Trasplante de Órganos y Tejidos, and Ministerio de Ciencia e Innovación (España)
- Subjects
Ertapenem ,medicine.medical_specialty ,Urinary system ,UTI ,Bacteremia ,Bloodstream infection ,BSI ,Logistic regression ,Extended-spectrum-b-lactamase-producing Enterobacterales ,Meropenem ,beta-Lactamases ,Cohort Studies ,chemistry.chemical_compound ,Internal medicine ,polycyclic compounds ,medicine ,Humans ,Pharmacology (medical) ,Propensity Score ,Kidney transplant ,Retrospective Studies ,Pharmacology ,Urinary tract infection ,business.industry ,ESBL-E ,Anti-Bacterial Agents ,Kidney Transplantation ,Urinary Tract Infections ,bacterial infections and mycoses ,medicine.disease ,Infectious Diseases ,chemistry ,Propensity score matching ,Cohort ,business ,medicine.drug ,Cohort study - Abstract
REIPI/ESGICH/ESGBIS/INCREMENT-SOT Group., There are scarce data on the efficacy of ertapenem in the treatment of bacteremia due to extended-spectrum-beta-lactamase (ESBL)-producing Enterobacterales (ESBL-E) in kidney transplant (KT) recipients. We evaluated the association between treatment with ertapenem or meropenem and clinical cure in KT recipients with nonsevere bacteremic urinary tract infections (B-UTI) caused by ESBL-E. We performed a registered, retrospective, international (29 centers in 14 countries) cohort study (INCREMENT-SOT, NCT02852902). The association between targeted therapy with ertapenem versus meropenem and clinical cure at day 14 (the principal outcome) was studied by logistic regression. Propensity score matching and desirability of outcome ranking (DOOR) analyses were also performed. A total of 201 patients were included; only 1 patient (treated with meropenem) in the cohort died. Clinical cure at day 14 was reached in 45/100 (45%) and 51/101 (50.5%) of patients treated with ertapenem and meropenem, respectively (adjusted OR 1.29; 95% CI 0.51 to 3.22; P = 0.76); the propensity score-matched cohort included 55 pairs (adjusted OR for clinical cure at day 14, 1.18; 95% CI 0.43 to 3.29; P = 0.74). In this cohort, the proportion of cases treated with ertapenem with better DOOR than with meropenem was 49.7% (95% CI, 40.4 to 59.1%) when hospital stay was considered. It ranged from 59 to 67% in different scenarios of a modified (weights-based) DOOR sensitivity analysis when potential ecological advantage or cost was considered in addition to outcome. In conclusion, targeted therapy with ertapenem appears as effective as meropenem to treat nonsevere B-UTI due to ESBL-E in KT recipients and may have some advantages., This work was supported by Plan Nacional de I+D+i 2013‐2016 and Instituto de Salud Carlos III (ISCIII), Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001, RD16/0016/0002, RD16/0016/0008; RD16/0016/00010) and was cofinanced by the European Development Regional Fund “A way to achieve Europe,” Operative program Intelligent Growth 2014‐2020; ESCMID Study Group for Infections in Compromised Hosts (ESGICH grant to J.M.A.); Sociedad Andaluza de Trasplante de Órgano Sólido (SATOT grant to L.M.-M.); ESCMID Study Group for Bloodstream Infections and Sepsis (ESGBIS); and ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS). B.G.-G. (PI 18/01849) and E.P.-N. (PI 16/01631) have received research funds from the Spanish Ministry of Science and Innovation, ISCIII; M.F.-R. holds a research contract “Miguel Servet” (CP 18/00073) from the Spanish Ministry of Science and Innovation, ISCIII.
- Published
- 2021
7. Episodi di attaccamento del paziente, interventi del terapeuta e rotture dell’alleanza: un’analisi microprocessuale
- Author
-
Colli, A., Gentile, Daniela, Taddei, P., Gervasi, E., and Lingiardi, Vittorio
- Subjects
interventi del terapeuta ,Rotture dell'alleanza terapeutica ,Attaccamento - Published
- 2011
8. Comportamento di Aeromonas hydrophila in campioni di pesce spada salato
- Author
-
Giuffrida, Alessandro, Giarratana, Filippo, Gervasi, E., Bucca, Mirella, Ruolo, Anna, and Ziino, Graziella
- Published
- 2009
9. Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study
- Author
-
Cicchiello, F., Riva, F., Cazzaniga, M. E., Pedani, F., Nicolini, Matteo, Butti, C., Liscia, N., Pogliani, C., Capri, Giorgia, Alu', Matteo, Febbraro, A., Petrucelli, L., D'Onofrio, L., De Laurentiis, M., Pellegrini, D., Mentuccia, L., Cocciolone, V., Miraglio, E., Bajardi, E., Dester, M., Paternò, Enrico, Guaitoli, G., Ferrarini, I., Gervasi, Elisea, Licata, L., Benedetto, C., Andreis, D., Bordin, E., Ancona, C., Pizzuti, L., Fotia, V., Berardi, R., Airoldi, M., Arcangeli, V., Artale, S., Atzori, F., Ballerio, A., Bianchi, G. V., Blasi, L., Campidoglio, S., Ciccarese, M., Cursano, M. C., Piezzo, M., Fabi, A., Ferrari, L., Ferzi, A., Ficorella, C., Frassoldati, A., Fumagalli, A., Garrone, O., Gebbia, V., Generali, D., La Verde, N., Maur, M., Michelotti, A., Moretti, G., Musolino, Anna, Palumbo, R., Pistelli, M., Porpiglia, M., Sartori, D., Scavelli, C., Schirone, A., Turletti, A., Valerio, M. R., Vici, P., Zambelli, Ruggero Astolfo, Clivio, L., Torri, V., Cicchiello, F, Riva, F, Cazzaniga, M, Pedani, F, Nicolini, M, Butti, C, Liscia, N, Pogliani, C, Capri, G, Alu, M, Febbraro, A, Petrucelli, L, D'Onofrio, L, De Laurentiis, M, Pellegrini, D, Mentuccia, L, Cocciolone, V, Miraglio, E, Bajardi, E, Dester, M, Paterno, E, Guaitoli, G, Ferrarini, I, Gervasi, E, Licata, L, Benedetto, C, Andreis, D, Bordin, E, Ancona, C, Pizzuti, L, Fotia, V, Berardi, R, Airoldi, M, Arcangeli, V, Artale, S, Atzori, F, Ballerio, A, Bianchi, G, Blasi, L, Campidoglio, S, Ciccarese, M, Cursano, M, Piezzo, M, Fabi, A, Ferrari, L, Ferzi, A, Ficorella, C, Frassoldati, A, Fumagalli, A, Garrone, O, Gebbia, V, Generali, D, La Verde, N, Maur, M, Michelotti, A, Moretti, G, Musolino, A, Palumbo, R, Pistelli, M, Porpiglia, M, Sartori, D, Scavelli, C, Schirone, A, Turletti, A, Valerio, M, Vici, P, Zambelli, A, Clivio, L, Torri, V, Cazzaniga, M. E, Bianchi, G. V, Cursano, M. C, Valerio, M. R, Torri, V., De Laurentiis, Michelino, Cicchiello, F., Riva, F., Cazzaniga, M. E., Pedani, F., Nicolini, M., Butti, C., Liscia, N., Pogliani, C., Capri, G., Alù, M., Febbraro, A., Petrucelli, L., D'Onofrio, L., De Laurentiis, M., Pellegrini, D., Mentuccia, L., Cocciolone, V., Miraglio, E., Bajardi, E., Dester, M., Paternò, E., Guaitoli, G., Ferrarini, I., Gervasi, E., Licata, L., Benedetto, C., Andreis, D., Bordin, E., Ancona, C., Pizzuti, L., Fotia, V., Berardi, R., Airoldi, M., Arcangeli, V., Artale, S., Atzori, F., Ballerio, A., Bianchi, G. V., Blasi, L., Campidoglio, S., Ciccarese, M., Cursano, M. C., Piezzo, M., Fabi, A., Ferrari, L., Ferzi, A., Ficorella, C., Frassoldati, A., Fumagalli, A., Garrone, O., Gebbia, V., Generali, D., La Verde, N., Maur, M., Michelotti, A., Moretti, G., Musolino, A., Palumbo, R., Pistelli, M., Porpiglia, M., Sartori, D., Scavelli, C., Schirone, A., Turletti, A., Valerio, M. R., Vici, P., Zambelli, A., Clivio, L., Cazzaniga, M., Ala, M., ARRIVAS BAJARDI, E., Paternã², E., Bianchi, G., Cursano, M., and Valerio, M.
- Subjects
0301 basic medicine ,Oncology ,Receptor, ErbB-2 ,chemistry.chemical_compound ,ErbB-2 ,0302 clinical medicine ,Dose-intensity ,Exemestane ,80 and over ,Neoplasm Metastasis ,Fulvestrant ,Aged, 80 and over ,education.field_of_study ,Advanced breast cancer, Dose-intensity, Everolimus, Fulvestrant, Hormone-receptor positive ,Advanced breast cancer ,Everolimus ,Hormone-receptor positive ,Adult ,Aged ,Androstadienes ,Breast Neoplasms ,Female ,Follow-Up Studies ,Humans ,Middle Aged ,Neoplasm Staging ,Surgery ,General Medicine ,Everolimu ,030220 oncology & carcinogenesis ,Receptor ,medicine.drug ,medicine.medical_specialty ,Population ,Socio-culturale ,03 medical and health sciences ,Breast cancer ,Internal medicine ,medicine ,Adverse effect ,education ,Gynecology ,business.industry ,fungi ,Cancer ,medicine.disease ,Clinical trial ,030104 developmental biology ,chemistry ,business - Abstract
Background The BOLERO-2 trial reported efficacy and safety of Everolimus (EVE) and Exemestane (EXE) combination in HR+ advanced breast cancer (ABC) patients. The BALLET trial further evaluated the safety of EVE-EXE in HR+ ABC patients, without reporting efficacy data. Aim of the EVA real-life study was to collect data of efficacy and safety of EVE-EXE combination in the clinical setting, as well as exploring efficacy according to EVE Dose-Intensity (DI) and to previous treatment with Fulvestrant. Patients and methods This study aimed to describe the outcome of ABC pts treated with EVE-EXE combination in terms of median duration of EVE treatment and ORR in a real-life setting. Results From July 2013 to December 2015, the EVA study enrolled 404 pts. Median age was 61 years (33–83). Main metastatic sites were: bone (69.1%), soft tissue (34.7%) and viscera (33.2%). Median number of previous treatments was 2 (1–7). 43.3% of the pts had received Fulvestrant. Median exposure to EVE was 31.0 weeks (15.4–58.3) in the whole population. No difference was observed in terms of EVE exposure duration according to DI (p for trend = 0.27) or type of previous treatments (p = 0.33). ORR and Disease Control Rate (DCR) were observed in 31.6% and 60.7% of the patients, respectively, with the lowest ORRs confined in CHT pre-treated patients or in those who received the lowest DI of EVE. Grade 3-4 adverse events (AEs) were reported in 37.9% of the patients. Main AEs were: stomatitis (11.2%), non-infectious pneumonitis - NIP (3.8%), anaemia (3.8%) and fatigue (3.2%). Conclusions The EVA study provided new insights in the use of EVE-EVE combination in HR+ ABC pts many years after the publication of the pivotal trial. The combination is safe and the best response could be obtained in patients receiving the full dose of EVE and/or after hormone-therapy as Fulvestrant in ABC.
- Published
- 2017
10. Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study
- Author
-
Nozza, Silvia, Malagoli, Andrea, Maia, Lilian, Calcagno, Andrea, Focã , Emanuele, De Socio, Giuseppe, Piconi, Stefania, Orofino, Giancarlo, Cattelan, Anna Maria, Celesia, Benedetto Maurizio, Gervasi, Elena, Guaraldi, Giovanni, Castagna, Antonella, Poli, Andrea, Galizzi, Nadia, Carli, Federica, Di Perri, Giovanni, Bonora, Stefano, Montrucchio, Chiara, Focã¡, Emanuele, Castelli, Francesco, Magro, Paola, Roldan, Eugenia Quiros, De Socio, Giuseppe Vittorio, Marinello, Serena, Farenga, Mariana, Cattela, Anna Maria, Marino, Andrea, Cacopardo, Bruno, Galli, Massimo, Riva, Agostino, Morena, Valeria, Nozza, S, Malagoli, A, Maia, L, Calcagno, A, Focà, E, De Socio, G, Piconi, S, Orofino, G, Cattelan, Am, Celesia, Bm, Gervasi, E, Guaraldi, G, on behalf the GEPPO Study, Group, and Castagna, A
- Subjects
Male ,0301 basic medicine ,Health Services for the Aged ,Cross-sectional study ,HIV Infections ,Cohort Studies ,0302 clinical medicine ,Antiretroviral Therapy, Highly Active ,Pharmacology (medical) ,Multiple Chronic Conditions ,Prospective Studies ,030212 general & internal medicine ,Practice Patterns, Physicians' ,Prospective cohort study ,Aged, 80 and over ,Geriatrics ,education.field_of_study ,virus diseases ,Middle Aged ,Viral Load ,Infectious Diseases ,Italy ,Cohort ,Female ,Cohort study ,Microbiology (medical) ,medicine.medical_specialty ,Anti-HIV Agents ,Population ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,Tenofovir ,education ,Aged ,Polypharmacy ,Pharmacology ,business.industry ,DRUG-DRUG INTERACTIONS ,INFECTED PATIENTS ,OLDER-ADULTS ,MYOCARDIAL-INFARCTION ,TENOFOVIR ,CRITERIA ,RISK ,POLYPHARMACY ,IMPACT ,TRIALS ,Antiretroviral therapy ,030112 virology ,Regimen ,Cross-Sectional Studies ,Logistic Models ,Hiv patients ,HIV-1 ,business - Abstract
Background GEPPO is a prospective observational multi-centric cohort including HIV-infected geriatric patients. We hypothesized that the GEPPO cohort may help characterize antiretroviral (ARV) prescribing criteria used in real life by Italian infectious disease (ID) physicians. Methods This was a cross-sectional study describing the current ARV regimen in a geriatric HIV population (≥65 years). Antiretroviral strategies were categorized as follows: (i) multidrug regimens (MDRs), which comprised triple or mega ART combinations; (ii) less drug regimens (LDRs), which comprised fewer than three ART compounds. Multi-morbidity (MM) was defined as the presence of three or more non-communicable diseases, and polypharmacy (PP) as the use of five or more medications in chronic use. Four alternative combinations (MM+PP+, MM+PP-, MM-PP+, MM-PP-) were used in logistic regression analyses. Results A total of 1222 HIV-positive patients were included (median age 70 years). Females composed 16% of the cohort. Median duration of HIV infection was 17 years; 335 population members had been infected for >20 years. MM was present in 64% and PP in 37% of the patients. Treatment consisted of triple therapy in 66.4%, dual therapy in 25.3%, monotherapy in 6.5% and 'mega-ART' with more than three drugs in 1.64% of the patients. In multivariate logistic regression MM and PP were predictive for mono-dual, NRTI-sparing and tenofovir disoproxil fumarate (TDF)-sparing combinations. Female gender and age were predictors of unboosted ARV regimens. Conclusions High prevalence of non-conventional ARV regimens in elderly HIV patients suggests that clinicians try to tailor ARV regimens according to age, HIV duration, MM and PP.
- Published
- 2017
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.